Haleos Labs LimitedHALEOSLABSCorporate

Pharmaceuticals Latest results: Jun 2026 15 quarters of data

₹1,532.40

MCap ₹463 Cr · P/E 30.4

Haleos Labs Limited — Stock analysis & AI research Haleos Labs Limited — Seasonality — best & worst months Haleos Labs Limited — Technical setup — score, trend, support & resistance Haleos Labs Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹73 Cr

Sales · Jun 2026

-11.6% YoY

₹9 Cr

Operating Profit · Jun 2026

-22.1% YoY

12.5%

OPM % · Jun 2026

-12.0% YoY

₹2 Cr

Net Profit · Jun 2026

-58.0% YoY

₹8.75

EPS · Jun 2026

-36.4% YoY

📝 Haleos Labs Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Haleos Labs Limited reported revenue of ₹73 crore for the quarter ended June 2026 (Q1 FY27), down 11.6% from ₹83 crore in the same quarter last year, and down 2.9% sequentially over the March 2026 quarter.

Net profit fell 58.0% year-on-year to ₹2 crore, from ₹4 crore. Earnings per share (EPS) came in at ₹8.75.

Operating profit stood at ₹9 crore — an operating margin (OPM) of 12.5%, compared with 14.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Haleos Labs Limited posted revenue of ₹334 crore, a decline of 3.2% over FY25, with a net profit of ₹18 crore (down 4.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹324 crore with a net profit of ₹15 crore.

Valuation snapshot

At the current price of ₹1,532.40, HALEOSLABS has a market capitalisation of ₹463 crore and a trailing P/E of about 30.4.

Within the Pharmaceuticals industry, it is the 14th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.11%, domestic institutional investors (DIIs) 0.31%, public shareholders 27.58% of Haleos Labs Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹463 Cr

Current Price ?

₹1,532.4

P/E ?

30.35above ind

Industry P/E ?

22.40

P/B ?

N/A

P/S ?

1.43

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

3.3%

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

₹324 Cr

OPM ?

12.6%

Profit after tax (TTM) ?

₹15 Cr

EPS (TTM) ?

₹50.49

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹73 Cr

PAT — latest qtr ?

₹2 Cr

YoY qtr sales growth ?

-11.6%

YoY qtr profit growth ?

-58.0%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

4.3

Current Ratio ?

N/A

Ownership

Promoter holding ?

72.11%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-2.5%

Return 6 months ?

18.4%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	88	64	75	69	72	90	93	78	85	89	83	81	95	75	73	-11.6%	-2.9%
Operating Profit	9	2	3	8	9	11	16	9	13	7	12	14	14	4	9	-22.1%	+119.2%
Other Income	1	2	1	0	1	2	0	2	0	2	1	0	0	2	0	-53.5%	-77.0%
Interest	2	2	2	3	2	3	2	2	2	2	2	2	2	1	2	+1.8%	+33.8%
Depreciation	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	+11.0%	+10.2%
Profit Before Tax	6	2	-3	2	4	7	11	5	7	4	7	8	9	1	3	-51.0%	+282.2%
Net Profit	4	2	-4	-0	4	6	7	3	5	3	4	6	7	0	2	-58.0%	+425.8%
EPS	13.18	5.66	-5.94	2.20	14.24	19.53	23.15	15.46	18.08	9.83	13.75	20.19	21.89	1.46	8.75	-36.4%	+499.3%
OPM %	10.6%	3.6%	3.4%	11.4%	12.9%	12.6%	17.6%	10.9%	15.1%	8.3%	14.2%	16.7%	14.8%	5.5%	12.5%	-12.0%	+127.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹345 Cr	₹334 Cr	₹324 Cr	-3.2%
Operating Profit	₹45 Cr	₹43 Cr	₹41 Cr	-3.4%
OPM %	13.06%	13.03%	12.61%	-0.2%
NPM %	5.43%	5.33%	4.71%	-1.8%
Other Income	₹5 Cr	₹4 Cr	₹3 Cr	-25.9%
Depreciation	₹15 Cr	₹15 Cr	₹16 Cr	+3.2%
Interest	₹9 Cr	₹6 Cr	₹6 Cr	-26.0%
EBIT	₹30 Cr	₹28 Cr	₹25 Cr	-6.7%
PBT	₹26 Cr	₹25 Cr	₹22 Cr	-3.8%
Tax	₹7 Cr	₹7 Cr	₹6 Cr	-8.4%
Net Profit	₹19 Cr	₹18 Cr	₹15 Cr	-4.9%
EPS	₹66.52	₹57.29	₹52.29	-13.9%
Material Cost	₹150 Cr	₹120 Cr	₹125 Cr	-20.1%
Employee Cost	₹60 Cr	₹49 Cr	₹50 Cr	-17.3%
Extraordinary Items	—	—	—	—

👥 Shareholding (latest 2 periods)

Metric	Jun 2026	Sep 2026	% Chg
Promoters	72.11%	72.11%	+0.0%
DIIs	0.31%	0.31%	+0.0%
Public	27.58%	27.58%	+0.0%
No. of Shareholders	6,859	6,765	-1.4%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	524636 Oxygenta Pharmaceutical	₹32.25	195	—	135	-14	-5.9%	-10.1%	3.3%	-70.8%	144.5%	65.6%

❓ Frequently asked questions

What was Haleos Labs Limited's revenue in Q1 FY27?

What was Haleos Labs Limited's net profit in Q1 FY27?